• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

痛风通过肠道微生物群和炎症介质导致代谢功能障碍相关脂肪性肝病。

Gout drives metabolic dysfunction-associated steatotic liver disease through gut microbiota and inflammatory mediators.

作者信息

Liu Siyuan, Li Fan, Cai Yunjia, Sun Lin, Ren Linan, Yin Mengsha, Cui Huijuan, Pan Yujie, Gang Xiaokun, Wang Guixia

机构信息

Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, 130021, Jilin, China.

Department of Hepatobiliary and Pancreatic Medicine, The First Hospital of Jilin University, Changchun, 130021, Jilin, China.

出版信息

Sci Rep. 2025 Mar 19;15(1):9395. doi: 10.1038/s41598-025-94118-7.

DOI:10.1038/s41598-025-94118-7
PMID:40102566
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11920238/
Abstract

This study explores the relationship between gout and metabolic dysfunction-associated steatotic liver disease (MASLD), two metabolic conditions linked to worsening health outcomes. While hyperuricemia's association with MASLD is established, the specific connection between gout and MASLD remains less explored. Using data from the UK Biobank, the study employs COX proportional hazard models, multi-state survival analysis, and Mendelian randomization to assess the independent and mutual risks of gout and MASLD. Findings indicate a mutual risk increase: male gout patients, those younger than 60, and those with high BMI are particularly susceptible to MASLD, while female MASLD patients are at heightened risk for gout. Shared risk factors for both conditions include high BMI, hypertension, diabetes, and hyperuricemia. The study further identifies a bidirectional causal link, with gout leading to MASLD, mediated by gut microbiota Ruminococcaceae and proteins like IL-2 and GDF11, implicating specific metabolic pathways. The findings highlight a clinical and mechanistic correlation, emphasizing the need for targeted interventions to address these overlapping metabolic pathways in future treatments.

摘要

本研究探讨痛风与代谢功能障碍相关脂肪性肝病(MASLD)之间的关系,这两种代谢状况都与健康状况恶化有关。虽然高尿酸血症与MASLD的关联已得到证实,但痛风与MASLD之间的具体联系仍有待深入研究。该研究利用英国生物银行的数据,采用COX比例风险模型、多状态生存分析和孟德尔随机化方法,评估痛风和MASLD的独立风险和共同风险。研究结果表明,二者的风险会共同增加:男性痛风患者、60岁以下人群以及高体重指数者尤其易患MASLD,而女性MASLD患者患痛风的风险更高。这两种病症的共同风险因素包括高体重指数、高血压、糖尿病和高尿酸血症。该研究进一步确定了一种双向因果关系,即痛风通过肠道微生物瘤胃球菌科以及白细胞介素-2和生长分化因子11等蛋白质介导导致MASLD,涉及特定的代谢途径。这些发现凸显了临床和机制上的相关性,强调在未来治疗中需要采取针对性干预措施来应对这些重叠的代谢途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96b3/11920238/293c303b1fd1/41598_2025_94118_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96b3/11920238/5212b5ea837d/41598_2025_94118_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96b3/11920238/8b7febe2cbc8/41598_2025_94118_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96b3/11920238/293c303b1fd1/41598_2025_94118_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96b3/11920238/5212b5ea837d/41598_2025_94118_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96b3/11920238/8b7febe2cbc8/41598_2025_94118_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96b3/11920238/293c303b1fd1/41598_2025_94118_Fig3_HTML.jpg

相似文献

1
Gout drives metabolic dysfunction-associated steatotic liver disease through gut microbiota and inflammatory mediators.痛风通过肠道微生物群和炎症介质导致代谢功能障碍相关脂肪性肝病。
Sci Rep. 2025 Mar 19;15(1):9395. doi: 10.1038/s41598-025-94118-7.
2
High salt diet causally increases metabolic dysfunction-associated steatotic liver disease risk: A bidirectional mendelian randomization study.高盐饮食因果性地增加代谢功能障碍相关脂肪性肝病风险:一项双向孟德尔随机化研究。
Nutr Res. 2025 Apr;136:94-104. doi: 10.1016/j.nutres.2025.03.004. Epub 2025 Mar 13.
3
Dietary inflammatory potential and metabolic (dysfunction)-associated steatotic liver disease and its complications: A comprehensive review.饮食炎症潜能与代谢(功能障碍)相关脂肪性肝病及其并发症:综述
Clin Nutr ESPEN. 2025 Feb;65:162-171. doi: 10.1016/j.clnesp.2024.11.032. Epub 2024 Nov 26.
4
Multi-omics analyses of the gut microbiota and metabolites in children with metabolic dysfunction-associated steatotic liver disease.代谢功能障碍相关脂肪性肝病患儿肠道微生物群和代谢物的多组学分析
mSystems. 2025 Apr 22;10(4):e0114824. doi: 10.1128/msystems.01148-24. Epub 2025 Mar 14.
5
Dietary Influences on Gut Microbiota and Their Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).饮食对肠道微生物群的影响及其在代谢功能障碍相关脂肪性肝病(MASLD)中的作用
Nutrients. 2024 Dec 31;17(1):143. doi: 10.3390/nu17010143.
6
Gut microbiota-based machine-learning signature for the diagnosis of alcohol-associated and metabolic dysfunction-associated steatotic liver disease.基于肠道微生物组的机器学习特征用于诊断酒精相关和代谢功能障碍相关脂肪性肝病。
Sci Rep. 2024 Jul 12;14(1):16122. doi: 10.1038/s41598-024-60768-2.
7
Characterization of gut dysbiosis and intestinal barrier dysfunction in patients with metabolic dysfunction-associated steatotic liver disease and chronic kidney disease: a comparative study.代谢功能障碍相关脂肪性肝病和慢性肾脏病患者肠道菌群失调及肠屏障功能障碍的特征:一项比较研究
Sci Rep. 2025 May 3;15(1):15481. doi: 10.1038/s41598-025-00237-6.
8
Interplay among IL1R1, gut microbiota, and bile acids in metabolic dysfunction-associated steatotic liver disease: a comprehensive review.白细胞介素1受体1、肠道微生物群和胆汁酸在代谢功能障碍相关脂肪性肝病中的相互作用:综述
J Gastroenterol Hepatol. 2025 Jan;40(1):33-40. doi: 10.1111/jgh.16750. Epub 2024 Sep 29.
9
Alteration of Gut Microbiota Composition in the Progression of Liver Damage in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).代谢功能障碍相关脂肪性肝病(MASLD)患者肝损伤进展过程中肠道微生物群组成的改变
Int J Mol Sci. 2024 Apr 16;25(8):4387. doi: 10.3390/ijms25084387.
10
Epidemiological Study on the Interaction between the (rs738409) and Gut Microbiota in Metabolic Dysfunction-Associated Steatotic Liver Disease.代谢相关脂肪性肝病中 (rs738409) 与肠道微生物群相互作用的流行病学研究。
Genes (Basel). 2024 Sep 6;15(9):1172. doi: 10.3390/genes15091172.

引用本文的文献

1
Triglyceride-glucose-waist circumference index: A powerful tool for metabolic dysfunction-associated steatotic liver disease.甘油三酯-血糖-腰围指数:代谢功能障碍相关脂肪性肝病的有力工具。
World J Hepatol. 2025 Jul 27;17(7):107668. doi: 10.4254/wjh.v17.i7.107668.
2
Unraveling the role of gut microbiota on the formation of nephrolithiasis: insights from integrated analysis of GWAS, single-cell transcriptomics, bulk RNA sequencing and network Pharmacology.解析肠道微生物群在肾结石形成中的作用:来自全基因组关联研究、单细胞转录组学、批量RNA测序和网络药理学综合分析的见解
Urolithiasis. 2025 Jul 15;53(1):138. doi: 10.1007/s00240-025-01809-x.

本文引用的文献

1
Hepatic glycogenesis antagonizes lipogenesis by blocking S1P via UDPG.肝糖生成通过 UDPG 阻断 S1P 来拮抗脂肪生成。
Science. 2024 Feb 16;383(6684):eadi3332. doi: 10.1126/science.adi3332.
2
MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.代谢相关脂肪性肝病:一种伴有心血管和恶性并发症的全身性代谢紊乱疾病。
Gut. 2024 Mar 7;73(4):691-702. doi: 10.1136/gutjnl-2023-330595.
3
A dynamics association study of gut barrier and microbiota in hyperuricemia.高尿酸血症中肠道屏障与微生物群的动力学关联研究
Front Microbiol. 2023 Nov 27;14:1287468. doi: 10.3389/fmicb.2023.1287468. eCollection 2023.
4
Composition of gut microbiota and non-alcoholic fatty liver disease: A systematic review and meta-analysis.肠道微生物群组成与非酒精性脂肪性肝病:系统评价和荟萃分析。
Obes Rev. 2024 Jan;25(1):e13646. doi: 10.1111/obr.13646. Epub 2023 Oct 9.
5
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review.代谢功能障碍相关脂肪性肝病(MASLD):最新综述
J Obes Metab Syndr. 2023 Sep 30;32(3):197-213. doi: 10.7570/jomes23052. Epub 2023 Sep 13.
6
Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress.RUNX1 抑制剂与吉西他滨联合通过调节 BiP/PERK/eIF2α 轴介导的内质网应激减轻胰腺导管腺癌的化疗耐药性。
J Exp Clin Cancer Res. 2023 Sep 11;42(1):238. doi: 10.1186/s13046-023-02814-x.
7
Mediation Analysis in Medical Research.医学研究中的中介分析。
Dtsch Arztebl Int. 2023 Oct 13;120(41):681-687. doi: 10.3238/arztebl.m2023.0175.
8
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.多学会专家组关于新的脂肪肝疾病命名的德尔菲共识声明。
J Hepatol. 2023 Dec;79(6):1542-1556. doi: 10.1016/j.jhep.2023.06.003. Epub 2023 Jun 24.
9
Association Between Serum Uric Acid and Non-Alcoholic Fatty Liver Disease: An Updated Systematic Review and Meta-Analysis.血清尿酸与非酒精性脂肪性肝病之间的关联:一项更新的系统评价与Meta分析
Clin Epidemiol. 2023 Jun 5;15:683-693. doi: 10.2147/CLEP.S403314. eCollection 2023.
10
Role of NLRP3 in the pathogenesis and treatment of gout arthritis.NLRP3 在痛风性关节炎发病机制和治疗中的作用。
Front Immunol. 2023 Mar 27;14:1137822. doi: 10.3389/fimmu.2023.1137822. eCollection 2023.